Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary
November 8, 2022
Earnings Call Speaker Segments
Operator
operatorHello, and thanks for joining us today. This is Bayer's conference call for investors and analysts covering our third quarter 2022 results. Right now, everyone is in a listen-only mode. Once the speaker finishes presenting, we'll open things up for questions and answers. If you'd like to ask something during that session, just press star one and one on your phone. You'll then get an automated message letting you know your hand has been raised. Please note that this call is being recorded today. At this point, I'll turn it over to Oliver Maier, Head of Investor Relations at Bayer AG. Over to you.
Oliver Maier
executiveOkay, thanks a lot, Heidi. Good afternoon, everyone, and thank you for being with us today. I'd like to welcome all of you to the conference call for our third quarter 2022. To make sure the audio quality is good, we kindly ask that you use a speaker and a landline rather than a headset or a cell phone, for instance. Joining me on the call today are Werner Baumann, our CEO, and Wolfgang Nickl, our CFO, and the businesses are represented by the responsible management board members for the Q&A session. Werner will kick off today's call with an overview of the key developments and achievements, and Wolfgang will then cover how our businesses performed and the outlook before we open up the Q&A session. As always, I'd like to begin today's call by drawing your attention to the cautionary language contained in our safe harbor statement, as well as in all the materials we have distributed today. Please also note that all net sales growth figures we reference in this call are on a currency and portfolio-adjusted basis, unless mentioned otherwise. With that, I'll hand it over to you, Werner.
Werner Baumann
executiveOkay. Thank you, Oliver, and good morning, everyone, and I appreciate you being with us today. I'd like to welcome each of you to the conference call for our third quarter of 2022. Following a very strong first half of the year, we increased our financial guidance for the entire year back in August. Through the third quarter results, we achieved continued robust operational performance, which places us squarely on course to hit our 2022 targets, along with investments and advancement in our pipeline that matter greatly for the years ahead. Although we are gaining from certain tailwinds, I want to emphasize that this year's results and our innovation-related progress rest on strong execution of our long-term growth strategy. Even as global supply chains faced mounting strain and inflation kept speeding up, we managed to expand our top line and lift our earnings during the third quarter in every business, building on a demanding comparable base from the prior year. Our Crop Science division posted yet another quarter of record sales, driven by the ongoing momentum in our herbicides business and a robust beginning to the season in Latin America. Year to date, Crop Science raised sales 17%, with industry-leading profitability and an EBITDA margin before special items above 30%.
Werner Baumann
executiveThis shows a substantial year-over-year margin gain, as efficiency initiatives and pricing did more than offset rising costs. In Pharmaceuticals, we saw 3% growth year-to-date, with Eylea posting a 10% increase, while Xarelto remains affected by volume-based procurement in China and by loss of exclusivity in Brazil. Sales of our new product Nubeqa nearly doubled during the first nine months of 2022. Our launch assets, Nubeqa and Kerendia, became the key growth drivers for the first time, contributing over half of the division's quarterly growth. In Consumer Health, we raised the top line by 9% year to date, driven in particular by allergy and cold, which rose 24%. The launch of Astepro is off to a good start — it is the first of its kind allergy solution for U.S. consumers, a steroid-free antihistamine spray that acts much faster than what is currently available on the market. On group profitability, we have offset accelerating inflation through efficiency measures across all divisions and, naturally, active pricing management, mainly in Crop Science and Consumer Health, while Pharma reimbursement remains under pressure. We expect the full effects of cost inflation across the value chain to actually materialize only next year. In addition to cost mitigation measures, we also keep managing our direct and indirect exposure around energy supply, as well as supply chain stability in a broader sense.
Werner Baumann
executiveWhen it comes to our German operations, we ought to be free of reliance on Russian gas by the close of this year. Even so, we keep seeing persistent strain on supply chains broadly, and absent those headwinds we could have expanded our business further in 2022. As we look toward the coming year, supply chain stability will remain crucially important for us. Right now we are adding more safety stocks, and we are working closely with suppliers and contract manufacturers to secure greater product availability and steadier supply chains. Our emphasis on health and nutrition has demonstrably boosted our resilience during crises. Following an already robust 2021, we remain on track for a very, very good 2022. That shows up beyond our operational results, since we keep hitting important innovation milestones. In pharmaceuticals, during quarter three we reached key pipeline advances that were on our agenda for this year, and these will support our acceleration of long-term growth beyond 2024. First, we achieved meaningful progress and cleared the path forward for our Factor XI inhibitor development program. With phase II study data for all three of our Factor XI candidates in hand, we chose to advance our orally administered compound, asundexian, into phase II in atrial fibrillation, as well as secondary stroke prevention.
Werner Baumann
executiveAssuming the trial succeeds, asundexian might reach the market as soon as 2026 — which means it could potentially align with the point at which Xarelto loses exclusivity in Europe. Since we hold full global rights to asundexian, it could also serve as a key cornerstone in our ambition to further expand our footprint in the U.S. With our Factor XI inhibitor program now centered on asundexian, and consistent with a disciplined approach to resource allocation, we have also decided to discontinue development of our two parenteral drug candidates, fesomersen and osocimab. Second, we've made significant progress on our marketed assets as well. In our ophthalmology franchise, very strong study data from the two phase II trials, PULSAR and PHOTON, showed that the vast majority of our patients with diabetic macular edema and age-related macular degeneration could be treated with aflibercept 8 mg every 16 weeks while benefiting from the same safety and efficacy profile of the lower dose Eylea. These results will now give patients and physicians the opportunity to effectively lower the number of annual treatments with aflibercept by up to 50%, thus providing strong arguments for higher convenience, adherence to therapy, and improved patient outcomes.
Werner Baumann
executiveWe're aiming to get aflibercept 8 mg out in our main markets by 2024. We believe its compelling value proposition will serve as a crucial pillar in protecting this product's leading market position even after the active ingredient patent expires, which across most of our markets happens in 2025. Lastly, we obtained significant U.S. label expansions for our launch products from the FDA. After the recent approval in the metastatic hormone-sensitive setting, Nubeqa, our innovative prostate cancer medicine, can now be prescribed for patients in the mid and late stages of the disease. In addition, Kerendia's label has been broadened to incorporate results from the phase III FIGARO-DKD study. This effectively complements Kerendia's use for patients at an earlier stage of chronic kidney disease with type 2 diabetes. On that note, we were also glad to see that just two weeks ago, KDIGO recommended adding Kerendia to SGLT-2 inhibitors for treating patients with chronic kidney disease and type 2 diabetes. Regarding Crop Science, we recently disclosed our agreement with Ginkgo Bioworks to further strengthen our position in biologicals via a multi-year strategic partnership aimed at speeding up research and development of biological products.
Werner Baumann
executiveYou're also seeing ongoing progress with Joyn Bio's novel nitrogen fixation platform, along with the exclusive rights to that technology. Turning to Consumer Health, the rollout of Astepro into the U.S. OTC market is going well and will provide a solid foundation for the coming allergy season. This is really a good illustration of how our businesses complement one another, since we applied our pharmaceutical regulatory expertise to help make that switch a success. With that experience behind us, we're confident about achieving additional switches down the road to fuel more growth. We've also gone further in streamlining the portfolio and concentrating on strategically relevant businesses. We completed the sale of the Environmental Science Professional business to Cinven at the start of October, and just last week we also finalized the divestment of Nebido, our testosterone therapy, to Grünenthal. Our investments extend beyond innovation as well. In early October, USAID named Bayer the anchor partner for its AGRI-Ukraine initiative, underscoring our planned investment of roughly EUR 35 million to expand capacity at our corn seed processing facility in Pochuiky. That facility is the biggest of its kind in Ukraine and, in fact, among the largest in Europe. Lastly, we keep advancing our ESG work and transparency, and we recently published the first sustainability progress report from our Crop Science division.
Werner Baumann
executiveAlso, in August, our ESG rating was raised by MSCI from BB to A. That upgrade came after the GMO red flag was removed, and it marks one more very significant milestone in strengthening our ESG profile. Wolfgang will now give you more detailed insight into how our businesses performed and what we expect going forward. With that, I'll turn things over to you, Wolfgang.
Wolfgang Nickl
executiveThanks, Werner, and hello everyone on the call from my side as well. During the third quarter, sales for the group rose 6% to EUR 11.3 billion, and every division contributed to that growth, with value-based pricing in Crop Science standing out most. Group EBITDA before special items was up 17% versus a year earlier, reaching EUR 2.5 billion. That produced a margin before special items of 21.7%. On foreign exchange, we continued to see a tailwind on revenue and a headwind on earnings before special items. The headwind arises from seasonally low revenues combined with a high cost base in U.S. dollar, plus the fact that we changed how we report the negative year-to-date currency impact of the Turkish lira and Argentine peso on earnings. I'll come back to the year-to-date FX impact later, since it gives a more representative picture for the full year. Core earnings per share were EUR 1.13, 8% higher than the prior year. That figure includes an unfavorable move in the core financial result of EUR 219 million, driven mainly by greater interest costs and non-cash relevant fair value changes on certain of our balance sheet positions. Our core tax rate rose to 25.9% in the third quarter, putting it at 22.4% on a year-to-date basis.
Wolfgang Nickl
executiveThat aligns with the 23% guidance we gave for the full year. Free cash flow came in at EUR 1.7 billion, down 11% versus the prior year. Cost inflation in inventories and the phasing of rebate payments are the main drivers of that reduction, and lower settlement payments and significant earnings growth were not enough to fully offset it. Net financial debt fell by roughly EUR 700 million, reaching EUR 35.9 billion at the close of the third quarter. Positive cash flow contributions were partly offset by a negative impact from the strong U.S dollar. Keep in mind that the net proceeds from closing the Environmental Science Professional divestment came in at the start of October and will show up in the Q4 results. Let's turn now to a closer look at what drove divisional performance in the third quarter. Crop Science posted very good Q3 results, with sales growth of 8% and a 34% rise in EBITDA before special items. For Crop Science, Q3 is typically the smallest quarter of our fiscal year in both sales and earnings. Herbicides carried on the trend seen in the first half of this year, with sales growth of more than 45%, largely driven by strong pricing for our glyphosate-based products.
Wolfgang Nickl
executiveLatin America also got the season off to a robust beginning, posting sales growth north of 30%, or roughly EUR 500 million. In that region, herbicide sales for corn and soybeans more than doubled, while insecticides turned in mid-teens percentage sales growth. On corn, we increased our global seed share for the 2022 crop year, even though planted acres in the United States came in lower. The 16% sales decline in the third quarter reflects higher returns stemming from reduced planted acres, along with somewhat lower licensing revenues. That was more than enough to offset mid-teens growth in LatAm. Soybean sales fell 8% on higher U.S. returns, which more than offset LatAm growth. Although seeds and trait share slipped somewhat in the U.S., we retained the number one trait position in both the U.S. and Brazil, reaching more than 50% and more than 80% of planted acres, respectively. We're also continuing to upgrade our footprint through the recently launched XtendFlex and Intacta, which extend our soybean trait offerings. These next-generation traits are foundational to the more than EUR 2 billion in seed and trait licensing revenue we earn each year.
Wolfgang Nickl
executiveLooking at the bottom line, earnings before special items rose to EUR 629 million — that's a 13.4% margin, up 120 basis points versus the prior year. Better pricing and mix thanks to new product introductions, plus savings from our ongoing efficiency programs, more than made up for lower volumes and roughly EUR 245 million of cost inflation, mainly in cost of goods sold. In Pharma, sales were up 3% and EBITDA before special items climbed 15%. As Werner mentioned, Nubeqa and Kerendia, our launch assets, were the main top-line growth drivers this quarter. We saw a similarly strong contribution from our IUD franchise, with double-digit growth driven by phasing and recovery from COVID-19 related effects. Eylea, once again, continued to beat our expectations, posting a 4% increase in the third quarter. Top line grew across every region, with the strongest contributions from Europe and China. Xarelto sales declined 8% in the third quarter. As expected, the key driver was again the impact of volume-based procurement in China, which by now should be largely absorbed on a year-on-year basis. On top of that, the loss of exclusivity in Brazil weighed on sales. Sales also got a boost from contract development and manufacturing milestones from our cell and gene and chemoproteomics platforms.
Wolfgang Nickl
executiveTurning to the bottom line, earnings before special items rose to EUR 1.5 billion, with a margin of 31.7%, which is 160 basis points higher than the prior year. That figure reflects the impact of the milestones mentioned earlier, along with gains from divesting non-strategic businesses. On top of that, we reallocated spending and sharpened where we put our R&D and marketing investments. Now let's turn to how our Consumer Health business performed. During Q3, we kept up our strong growth trajectory in every region, with sales growth of 4% on top of a high prior year comparable, and earnings up 9%. Demand stayed high for our cough and cold products, which grew because of a higher number of cold incidences. Sales for our allergy portfolio also rose, and we're seeing positive momentum for our Astepro launch in the United States OTC market. Altogether, that produced 17% growth for the allergy and cold category. In Nutritionals, we saw the normalization we expected, in line with market development, with an 8% sales decline in the quarter on a higher level in absolute terms. Strong sales growth translated into earnings before special items of EUR 336 million, while margin came in 120 basis points below previous year at 21.7%, mainly driven by higher commercial investments, in particular for the launch of Astepro.
Wolfgang Nickl
executiveNow let's turn to how we've performed so far this year. I'll begin with the primary factors behind our top-line expansion. Price is the main force propelling the group's total sales growth year to date in Crop Science and Consumer Health. Pharma, by contrast, posted a negative pricing effect. Within Crop Science, pricing on glyphosate-based herbicide brought in close to EUR 1.9 billion across the first nine months. We held onto a brand premium relative to generics coming out of China, where supply was tight. Market prices during Q3 declined relative to the first half of the year, and looking ahead we anticipate additional normalization in Q4 and next year. Above all, beyond the glyphosate dynamics, we are likewise delivering mid-single-digit percentage price improvements in corn, fungicides, insecticides, and other herbicides, which rounds out growth in Crop Science this year. For the 2023 season, we have already announced branded seed pricing for corn and soy in the U.S. and for corn in Europe, and we expect to deliver average low double-digit percentage price increases. In Consumer Health, we recorded broad-based pricing growth of 6% across categories. Meanwhile, we are beginning to see selective price elasticity affecting demand, even as consumers keep valuing the superior brand benefits of Bayer.
Wolfgang Nickl
executiveWhen it comes to Pharmaceuticals, the expansion we recorded during the opening nine months of this year came entirely from volume. Overall, we experienced an unfavorable pricing impact stemming from volume-based procurement for Xarelto in China, along with pricing that was largely fixed across the board. Up to now, we have not observed a meaningful effect from volume-based procurement for Adalat, and we anticipate that it will begin in Q4 and reach full effect next year. Turning to the bottom line, as I noted earlier, every one of our divisions is feeling substantial cost inflation across input materials, energy, freight, warehousing, and personnel. That cost inflation impact is especially pronounced in Crop Science, amounting to roughly 4% of net sales, or about EUR 700 million. Pharma is affected to the tune of EUR 450 million, while Consumer Health faces around EUR 180 million year to date versus the prior year. We anticipate the complete cost inflation effects throughout the value chain will show up next year, and we will keep actively managing these pressures through efficiencies and pricing wherever we can. Exchange rates are another factor. Year to date, we gained from meaningful tailwinds of approximately EUR 2.4 billion in sales and about EUR 290 million in earnings before special items. That produces a year-to-date margin dilution of 110 basis points. According to our latest estimate, which relies on September month-end spot rates, we expect margin dilution to decline to roughly 70 basis points by the close of the year.
Wolfgang Nickl
executiveGiven the robust performance we've seen so far this year, we remain firmly on course to deliver the group's full-year growth and P&L guidance for 2022. In Crop Science and Consumer Health, there is a bit of upside potential, while the targets in Pharma stay demanding. We reaffirm the group P&L outlook and the core EPS guidance that was upgraded in August, which now incorporates the impact of the Environmental Science divestment. Our free cash flow guidance has been raised by EUR 500 million, bringing it to roughly EUR 3 billion at constant currencies, reflecting net settlement payments that came in lower than expected. We have also revised our net financial debt guidance to reflect the higher free cash flow along with the completion of the Environmental Science Professional divestment. At constant currencies, net debt is now anticipated to land at about EUR 31 billion by year-end. In the right-hand column, you'll see the updated foreign exchange estimate based on the latest rates as of the end of September. These most recent movements now point to an estimated tailwind of approximately EUR 3.5 billion in net sales, along with a dilutive impact on margin of 70 basis points, as I noted earlier. I should also mention that the strong U.S. dollar will add roughly EUR 2 billion to net financial debt when end of September exchange rates are applied.
Wolfgang Nickl
executiveWith that said, I'll turn the call back to you, Oliver, so we can begin the Q&A.
Oliver Maier
executiveThanks. Appreciate it, Wolfgang. And Werner, thanks for walking us through that. Just before we get going, my usual reminder: please limit yourselves to roughly two questions apiece, since that lets us field questions from as many of you joining as we can. With that said, Heidi, let's go ahead and open the Q&A portion, please.
Operator
operatorThanks. Just a quick reminder that if you'd like to ask something, press star one and one on your phone, then hold until your name is called. Our first question is from Michael Leuchten at UBS. Go ahead.
Michael Leuchten
analystOh, thank you so much. This is Michael Leuchten calling from UBS. First, I appreciate all the granularity regarding the various components as we look ahead to 2023. I was simply wondering whether you might be able to synthesize that for us. It seemed as though the key factors determining where margins in Crop Science end up in 2023 really come down to glyphosate pricing, in light of the price hikes you mentioned across the portfolio. And on that note, can you offset the inflationary costs within the Crop Science business through those price increases, or does the inflation pressure go beyond that? Thank you.
Wolfgang Nickl
executiveI can probably kick things off, and then Wolfgang and Werner can add to it. I'm glad to go over some of the vectors again that described it. As a safe harbor, we're providing some vectors so you can orient yourselves, but today we aren't giving specific guidance for 2023. I mean, in this environment they're pretty volatile, and we'll do that in Q1 as usual. I think the components for Crop Science and others can chime in on is certainly pricing. I mean, in the first nine months we've seen glyphosate pricing at EUR 1.9 billion above the same period of the prior year. I think Q3 was lower than what we saw in the first half of the year. We expect pricing to further normalize into Q4 and next year. Of course, what we're trying to do is offset some of this with price increases in other areas. I gave you the soy and corn example for the U.S. For next year and in corn for Europe, where we have double-digit price increases. Inflation is a big deal, that's why we pointed out what it is for the first nine months. One of the important things, Michael, that you need to consider is that some of the inflation is still showing in inventory.
Wolfgang Nickl
executiveYou've likely noticed this in our cash flow statements, and it's simply the result of first in, first out: the cheaper inventory purchased earlier gets consumed in the P&L sooner, and then the following year carries a somewhat heavier burden. I'd also like to highlight — and I'm sure your models capture this too, Michael — that we're obviously very pleased to have successfully divested our Environmental Science business at a highly attractive rate. As you may remember, that business had roughly EUR 600 million in top line and about 1/3 of that in EBITDA. You can work out the impact yourself, since this year only three months are missing, but next year a full year is missing. That's a brief rundown of the Crop Science-related part, but Rodrigo or Werner, please feel free to chime in.
Werner Baumann
executiveRight. Perhaps I can just quickly build on what Wolfgang mentioned. I'll begin by repeating what I noted during my opening comments. We're having a really robust 2022, one that has basically carried us into the range we set out in our 2024 guidance. Part of that, naturally, comes from the substantial cyclical tailwind our Crop Science business provides. As Wolfgang already noted, certain pieces of it won't remain at the level we're witnessing in 2022. With glyphosate average prices, which are, as you know, considerably above what we're seeing in quarter three, and in all probability, will be somewhat lower even in quarter four before we head into 2023. That's a key factor to keep an eye on. Second, on pricing — and Rodrigo can go into greater detail on this. Pricing has been raised fairly, you know, meaningfully throughout the whole crop portfolio in response to the cost increases we're encountering across that portfolio. To be very clear, this isn't solely a glyphosate matter. That holds for 2022, and it also holds for the price reductions Wolfgang already mentioned as we move into 2023.
Werner Baumann
executiveIn our Consumer business, you’ll see additional moves of the same kind—raising prices to offset inflation and then safeguard margin. And finally, before I turn things over to Rodrigo, the situation in pharma is, naturally, quite different. We’re facing the same inflationary strain on the cost-of-goods side, with cost of goods relatively low—a bit lower—but we also have salary and wage inflation that will hit in full during 2023. At the same time, we can’t raise prices, because we happen to operate within regulatory systems, and beyond that, there are further top-line effects from the Xarelto LOEs across various countries, plus volume-based procurement, which has been with us certainly in 2021 and 2022 on Xarelto and, now with Adalat moving into 2023, one very important product that will be affected as well. Those are the points to keep in mind: in terms of pricing, we also have different businesses with different exposures, to the extent that they can carry inflation through with higher pricing. With that, Rodrigo, please.
Rodrigo Santos
executiveNo, Michael. And just to add to that — Werner and Wolfgang did a great job explaining the pricing work we're doing. I think there's just one more piece of information to add, which is our efficiency programs, right? We're putting a lot of effort into that as well. Just to give you a number for 2022, by the end of this year, we're expecting EUR 200 million of savings from our efficiency programs. When you think about 2023, of course, we're gonna keep doing a lot of work with our supply team when it comes to cost management, efficiency programs, supply resilience to help us. That equation of tackling inflation through pricing and our efficiency programs to help us drive what we planned for the next years.
Michael Leuchten
analystI appreciate that.
Rodrigo Santos
executiveThanks, Michael.
Operator
operatorThank you. We'll move on to the next question. That question is from Richard Vosser at JPMorgan. Please go ahead. Your line is open.
Richard Vosser
analystHello, and thank you very much. I have two questions, if I may. First, going back to crop and thinking about acreages: I believe acreage is clearly lower in the U.S. this year. I have seen some early signals that corn acreage is rising by roughly 5%, or returning to what you might call very high levels. Is that how you see it? Your perspective on how soybean acreage is developing—which I believe may be somewhat lower—would also be quite helpful. My second question concerns the discontinuation of the Factor VIII gene therapy program. Does this signal a reprioritization away from gene therapy? And an update on the cell therapy work at BlueRock Therapeutics would also be of interest. Thank you very much.
Werner Baumann
executiveOkay, Richard. Rodrigo will handle the first question, and after that Stefan will cover gene therapy along with the Factor XI program.
Rodrigo Santos
executiveRichard, the quick response is that you've got it right. We're looking at the coming year. As you know, it's too early, correct? When you consider the commodity cycle we're in, plus the USDA's yield adjustments for the U.S. and the drought problem in Europe, there's concern regarding grain supply in the market. We expect another favorable commodity cycle next year, which ought to drive an increase in corn acreage, particularly in the U.S., given the comparison with this year. Soybeans are clearly kind of the same, but corn, I believe, is the primary driver because of what took place this year in the U.S. We had close to 4 million acres or 5 million acres fewer owing to weather conditions. We should see that occur next year. In line with that, my last remark, Richard, before I hand over to Stefan here, is that we're observing, when you look at the order book, the demand for high technology, the top hybrids in our portfolio, and the innovation we have. That's a solid signal, when we see it, of what we anticipate for the next season.
Rodrigo Santos
executiveThanks for the question, Stefan.
Stefan Oelrich
executiveYes. Thank you, Rodrigo. Hello, Richard. Let me be very clear: Ultragenyx getting back the rights to our DTX201 compound for treating hemophilia via gene therapy has nothing to do with any reprioritization of our gene therapy work. Quite the opposite — we remain very pleased with how our clinical-stage gene therapy pipeline is progressing, largely coming out of our AskBio acquisition. This particular one does return to Ultragenyx, and they now hold the full rights to the compound once again. On your cell therapy question: what I can say is that we have fully enrolled our phase I cohort for cell therapy in Parkinson's, and we hope to bring you the one-year data for the first cohort very soon. Just to give you a sense, we should have that around the middle of next year — one year for the full cohort — and the data should be ready then. I can't say more at this point, but stay tuned. This is something we feel extremely excited about.
Operator
operatorThanks. We’ll move on to the next question. Our next question is from Peter Verdult at Citi. Please go ahead. Your line is open.
Peter Verdult
analystThank you. Peter Verdult from Citi, with two questions. I'll start with Stefan. Given where things are heading right now, when does Kerendia become one of Bayer's top 15 products? It seems hard to believe that you're highlighting it as delivering nearly 50% of the division's growth while not disclosing its sales. Could you give us some guidance, Stefan, on when, on the current trajectory, Kerendia will rank among Biopharma's top 15 products? And now that the Eylea 16-week data has had time to settle and you know what competitors are saying, what do you think you can achieve with that asset in markets outside the U.S.? It's very clear that the market cap move following that data was stark between you and your U.S. partner. Rodrigo, let me return to crop. Instead of asking you to repeat the same input you've given for the last two questions, I suppose it really boils down to this: consensus for next year has low single-digit revenue declines and a relatively modest margin impact. We're somewhat more aggressive to the downside, but I wanted to keep it tight and get a sense check from you on how comfortable or not you are given where expectations currently sit.
Peter Verdult
analystI appreciate that.
Werner Baumann
executiveOkay, so Stefan will kick things off, and after that, Rodrigo will take over.
Stefan Oelrich
executiveAppreciate that, Peter. Regarding Kerendia, yes, we're quite happy with the performance we're seeing right across the board. And we're going to be starting in China now as well, following a really strong U.S. launch. I'm sure you're following this just as I am, looking at how it stacks up against other products in the category that have launched, and I think we continue to track at or above some comparables in the class. When will it reach the top products? Typically I don't provide guidance in November for the year that follows, but we're also quite confident about next year and then hope to share a bit more detail with you, including numbers. On Eylea 8 mg, we should receive approval for it outside the U.S. by the first quarter of 2024. This is obviously data that I think anyone who has reviewed it has seen shows there is more than just life now in Eylea. This is unprecedented data with the dosing intervals, which beats every published competitor to this day. We feel this is going to give additional, let's say, life to this franchise beyond and above the loss of exclusivity of the 2-mg formulation.
Rodrigo Santos
executivePete, I’ll take that question. Of course, we’re already operating in 2023, and it’s too early to provide guidance for next year. Let me use your question to step back for a moment and reinforce a bit of my perspective on the market and on how we’re performing, right? We finished 2021 with a very strong result that was above the market. With the results we’re seeing today — 17% sales growth in the first nine months of the year and a 30% EBITDA margin — and when you look at how the business is performing, we are leading in corn, soybean, herbicides, biologicals, digital, and new frontiers such as carbon. Clearly, what we’re seeing this year reinforces our mid- and long-term strategy and our investment in R&D, along with the results of innovation reaching the market. Again, of course, we’re still working on next year. We shared some vectors today, but we can’t give a more precise answer for next year.
Peter Verdult
analystAppreciate it.
Operator
operatorThanks. We'll move on to our next question. Our next question is from Vincent Andrews at Morgan Stanley. Please go ahead. Your line is open.
Vincent Andrews
analystThanks, and good morning to everyone. Rodrigo, I wanted to see whether you can help us connect how U.S. soybeans did this year with what you expect for next year. In a couple of respects, I’d like to understand what your volume and price mix looked like this year compared with what you’re expecting given the double-digit price increase for next year. From a share standpoint, do you believe you’ve reached a point where you can hold the market share you currently have, or do you think you could regain some next year, or does some risk remain that you lose a little? And how much of that, I guess, depends on XtendFlex?
Rodrigo Santos
executiveThanks, Vincent. Let me begin at the end here. I believe you hit the nail on the head, correct? If you consider the whole group on this call today, and if you consider recent years, what happened is, naturally, as Corteva moved their platform over from ours to Enlist, you could observe Enlist's penetration rising in the market. As for the years ahead, it's going to be head-to-head competition, right? A lot will hinge on how the varieties perform in the market, and that's the reason we feel confident about next year, when we'll compete in this market. We remain the number one platform in the market, holding more than 50% of it. Very important, as you mentioned, this year we reached 20 million acres of XtendFlex. The new varieties, the precision breeding we're seeing in the market, are helping. Last year, we had a 2.5 bushels per acre advantage, and we're still gathering the data this year, but we are seeing very good results. What I'd say is that, in the years ahead, we're going to see very head-to-head competition in the market, and we are confident in the plans we have.
Rodrigo Santos
executiveNaturally, getting the launch ready for the next next-generation, you know, the HT4. Beyond that, I'll take advantage of this question too, Vincent, to underline the point about Latam, correct? So if you consider soybean, LatAm, Brazil in particular, has become hugely important. Our penetration in that market stands above 80%. We're advancing toward 6 million acres of Intacta 2 Xtend, and performance there is extremely solid as well. To be more specific, looking at this year's quarter, you had an effect from excess seed. That is essentially also an impact we observed in the numbers, specifically regarding the quarter. Confirming your point, in the years ahead, we're going to see competition that is much more head-to-head, along with the importance of the varieties. The yield component in the market will matter a great deal over the coming years.
Vincent Andrews
analystThanks. As a follow-up, I just want to ask about the PCB litigation. The quarterly documents mention that in August you filed a complaint seeking to enforce rights under certain indemnification contracts. Could you talk about what the scope of that might be if you succeed and prevail on those? What portion of the PCB liabilities could indemnification cover, and what timeframe do you think it will take to see whether you can get a court ruling in your favor on that?
Werner Baumann
executiveYes, Vincent. Appreciate the question. Werner here. To start with, we've filed suit against every one of the major so-called undertakers — those are the customers of ours that granted us full recourse. That goes back to their commitment letters in the early 1970s, a time when they lacked access to alternative products, especially fire-retardant ones. Because of that, the recourse we hold is not time-barred. It's open-ended and all-inclusive, and that is exactly what we're pursuing. As for court, we don't have a view on that where timing is concerned. This is, you know, a parallel process — you've got a court proceeding running, and then naturally, negotiations with each of the underwriters.
Vincent Andrews
analystAlright, thanks a lot. I really appreciate that.
Operator
operatorThanks. We’ll move on to the next question. Our next question is from Laurent Favre at Exane BNP Paribas. Please go ahead. Your line is open.
Laurent Favre
analystThanks. Good afternoon, everyone. That leaves me with just a single question, and it's directed at Rodrigo regarding the efficiency savings — EUR 200 million for 2022. Could you possibly provide a figure for 2023 as well?
Rodrigo Santos
executiveLaurent, unfortunately, that item is still in progress. Giving you an exact figure at this point would be premature. What I can say is that we're collaborating with the organization on the efficiency initiatives we've got underway, along with the supply cost management we're implementing, and on supply resilience too. Thinking about the coming 2 or 3 years, working on the top line — which we've stressed many times today — but also on the bottom line and how we deliver those efficiencies, that's a really key piece. Another item you noticed in the market, the Environmental Science that Wolfgang mentioned, and looking back a bit, we also made certain portfolio adjustments in Crop Science to drive better margins going forward. I'll revisit that question early next year, once we have the Q4 results as well.
Laurent Favre
analystThanks. Wolfgang, you actually brought that up.
Wolfgang Nickl
executiveLaurent, let me add a small reminder for everyone listening. As you may remember, back in 2020 we commissioned an efficiency program that takes effect across 2023, 2024, and 2025, and we stated it would be EUR 1.5 billion plus. So when you think about overall modeling, for 2023, 2024, and 2025, you can assume it's almost linear. It isn't precise yet. As Rodrigo mentioned, we're still working through the details, but I think it matters that you factor that in when building your longer-term models. Sorry, you had a second question.
Laurent Favre
analystYeah, sorry about that. Wolfgang, you brought up how rebates affected free cash flow this quarter versus last year. I'm wondering whether that impact is largely a timing thing, or whether you're expanding the rebates program in order to defend market share?
Wolfgang Nickl
executiveLaurent, that’s purely a matter of timing.
Laurent Favre
analystThanks.
Operator
operatorThanks. We'll move on to the next question. Our next question is from Keyur Parekh at Goldman Sachs. Your line is open — go ahead.
Keyur Parekh
analystHello, and thanks. I have two questions, if that's all right. First, back to crop. I'm curious how you're viewing the corn-versus-soy planting split in the Northern Hemisphere for next year. Obviously, this year's corn acreage being lower by 5 million acres sets up an easier year-over-year comparison, but is there any early indication or any sense you can offer about how we should think about that broader corn versus soy split next year? Second, still on crop, I'm wondering how you see the market share dynamics in crop chemicals. It appears that the volume growth reported year-to-date by the rest of your peers, Corteva included, is considerably higher than what we're seeing from Bayer. So I'm just wondering how you're thinking about volume in that part of the business. Thank you.
Rodrigo Santos
executiveThanks, Keyur. I'll take the questions now, and if any of my peers here have other comments, I'm open to those as well. On corn and soybean, what I'd tell you today is this: when you put demand together with supply — and I mentioned some of the challenges we're seeing on supply, on yield, because of weather conditions in Europe and a little of what happened in the U.S. when we had the planting season here — I'd say the trend is more toward an increase in corn next year versus soybean. We still see a soybean area that will be significant, but the trending, if I had to give you an answer, is more toward corn. On crop protection volume, I'd say let's see by the closing of the fiscal year, because we have a lot of the dynamics of quarters and how they play the quarters in that market. We feel very good about our performance in herbicides — of course, this is a market we lead, and we're in a very strong position in that one. But also on the fungicide side, where we hold the number two position, and insecticide, where we hold the number three position, we are seeing a lot of good development.
Rodrigo Santos
executiveWe launched products in the market, including the Adengo expansion and the Fox family in Brazil, and I believe that the—when I look at the fungicide market, we're excited about next year. That's probably one of the things we're pushing for next year: the fungicide market, as you mentioned. Insecticides too. We've just had a very important launch with Curbix, which will be a major launch for us, and we're expanding it in the market. Let me tell you that we have very strong performance. For crop protection as well. We're managing very low channel inventory in the market because of the dynamics and the volatility that Wolfgang mentioned today on the call. Let's see. As we close this year, I'd say we're confident that we're going to have a very good performance in crop protection as well. Thank you.
Operator
operatorThanks. We’ll move on to our next question. Our next question is from James Quigley at Morgan Stanley. Please go ahead. Your line is open.
James Quigley
analystHi there. Thanks for the questions. I have another one that follows up on the Kerendia launch. According to IMS data, it looks like roughly $100 million for the first nine months of the year, and September showed a significant jump to approximately $23 million. Does that generally match what you are observing? Are there any other considerations we should keep in mind as we track the Kerendia launch through IMS? I believe Werner also brought up the guideline changes for Kerendia earlier, or a couple of weeks ago. How much of that will be incremental? Were physicians already prescribing Kerendia on top of SGLT-2s, or will this represent an additional source of upside for the launch? Then, turning to the Consumer business, you again mentioned the Rx-to-OTC switches, and Astepro has done well and you plan to do this again — how many potential Rx-to-OTC switches are in the pipeline? When could they launch? And typically, based on what you have seen historically in your business, what growth impact would you cite for Rx-to-OTC switches in the year of a launch? Thank you.
Werner Baumann
executiveOkay, James. Stefan will kick things off, and after that, Heiko is going to handle the question about the OTC switch.
Stefan Oelrich
executiveYeah. First off, I’m not sure I can really answer your first question. Since there’s a gross-to-net in between, I won’t confirm or deny it, because otherwise I’d be making a forward-looking statement for the year. Again, I think you’re right. You’re seeing—we’re seeing the TRx uptick, which is really nice, coming out of the U.S. Again, China should be following suit soon. For this year, overall, let’s say you’re not that far away. On the SGLT-2 question, James, could you please say again what exactly you needed on the SGLT-2 opportunity?
James Quigley
analystBased on what you're seeing up to now, are physicians already prescribing Kerendia alongside SGLT-2s? Or how would you characterize the KDIGO guideline updates — do they incrementally suggest, permit, or recommend using Kerendia and SGLT-2s in combination?
Stefan Oelrich
executiveWhat we're observing across every set of guidelines—not only the KDIGO ones, but also those from ADA and others—is that Kerendia now holds a very prominent position, sitting on top of SGLT-2, which makes a lot of sense. If SGLT-2 is already part of the base case for treating diabetes, that works. From what I understand, if you aren't using SGLT-2 as a baseline and you want to treat kidney ailment, you can go straight to Kerendia as well under this guideline. We're seeing that we're building real headroom and turning into a foundational treatment for kidney patients. In our existing base, we're seeing a good number of patients on SGLT-2 to whom you add Kerendia. We're also seeing plenty of patients not yet on SGLT-2 who are getting onto Kerendia early. Keep in mind that with type 2 diabetes, the vast majority of diabetics who are being treated and who develop kidney disease are not currently on SGLT-2. We believe we're well-placed both in combination and as a foundational therapy for kidney. That's at least how I read the guidelines too—very, very nicely covered by them. What you have to note is that all the major colleges out there now, the physician colleges, are recommending Kerendia's use in a very broad patient population.
Heiko Schipper
executiveAlright, a few quick remarks about Rx-to-OTC switches. We genuinely favor these, for a few reasons. It delivers genuine innovation into Consumer Health. Our customers are big fans since it makes their categories bigger. And naturally, for consumers it's quite advantageous, because these products tend to be stronger propositions, which is what we're seeing as well with the Astepro launch. So it provides solid incremental innovation. The final reason we at Bayer are especially fond of it is that we believe we hold competitive capabilities in this area that not everyone possesses. Taking a product from Rx to OTC requires a solid grasp of regulatory affairs and managing that, securing FDA approval in this instance, since this is a U.S. launch. You have to know how to handle those steps. That isn't so simple. Not everybody can pull those off successfully. We believe our team there is very strong. So obviously we don't intend to restrict this to Astepro alone. In fact, we're developing a pipeline. I'd rather not go into the full specifics right now of everything we have planned on the innovation front over the next few years.
Heiko Schipper
executiveNaturally, we’ll put those out as soon as we’re able to, once the competitive timing is right for doing so. It’s clear this will stay a key element of our strategy. During this quarter, we witnessed it right away. It produced double-digit growth in allergy immediately. It is highly incremental. Of course, it also involves a fair amount of investment, since these tend to be new brands. Because it’s a new active ingredient, we must establish a new brand name. Introducing a new brand name in the U.S. is not inexpensive, yet the investment pays off. The ROIs on it are very strong, and it represents genuine innovation that I believe consumers expect from Bayer in this category.
James Quigley
analystAll right, thanks a lot.
Operator
operatorThanks. We’ll move on to our next question. Our next question is from Sachin Jain at Bank of America. Please go ahead. Your line is open.
Sachin Jain
analystHello. Thank you for taking my questions. I have a couple, if I may. First, during your introductory remarks about guidance, I believe you mentioned that pharma guidance could be challenging, with upside in crop. So I was wondering whether you might provide a little more detail on where those challenges lie within that pharma guidance. My assumption is that it's on the margin side, and if so, do those pressures carry on into next year?
Werner Baumann
executiveMm-hmm. Second, let me take a shot at the glyphosate pricing question. On normalization, can you offer any directional view of where that lands in 2023, and how should we think about glyphosate pricing in 2023 relative to the EUR 2.1 billion to EUR 2.2 billion, I suppose, that you finish this year at? The last question concerns PCB, on a somewhat different note, for Werner, similar to the earlier question. What are the pivot points for you in weighing whether additional provisions are needed for this beyond what you have already taken, given that since the second quarter call, more states and some personal injury claims have come in? Thank you very much. All right, Sachin, this is Werner. Good morning, and thanks for your three questions. First of all, I mean, when it comes to where the challenges lie for the guidance, it's clear that for pharma, the challenge is a margin one. You can see that already. We are, you know, quite a bit stretched because of the effects that I mentioned earlier. On top of that, we have a few other things that we touched on, e.g., the continued difficult environment for pharma in China, where normal commercial activities are not possible.
Werner Baumann
executiveTo be honest, I was actually in Beijing roughly 3 days back, and the situation there is quite unlike what you'd call a typical setting. Folks aren't able to go about their business as usual, and the same applies to our commercial team. Since our China business matters a great deal, that naturally has an effect. Second, the FX hit on our Pharma business is outsized. That also presses hard on the margin picture, meaning we see what you might call inflationary growth at the top line, yet get considerably less of it at the bottom line — in fact, to the point where it turns negative, as an example, for the quarter. That burdens the Pharma business. Now, Rodrigo has already noted that we're at 17% year-to-date, top line up, and with one more quarter still to come, there's, shall we say, a prospect that this quarter might even come in a touch better. We haven't adjusted for it, because all things considered, it wouldn't have altered the guidance for the company. So that's everything worth saying on pharma and crop. What you should take away is that, for the company, it makes no difference, though the makeup of the delivery is potentially going to look somewhat different.
Werner Baumann
executiveRegarding glyphosate normalization, we don't anticipate your prices falling back to where they were at the close of 2020 or in early 2021, since costs have risen for generic producers. Logistics expenses are extremely high, and that will always be a key factor driving the cost base for our competitors. Naturally, we benefit from vertical integration in our Glyphosate operation. That said, as we head into 2023, we do not expect average pricing to be anywhere close to what we're seeing in 2022. Right. The simplest approach for you is to examine the generic glyphosate pricing curve, where it averages out during 2022, then simply take the end of quarter three as you move into quarter four — what you observe there serves as a solid proxy. We are, you know, we're going into the year and that's the foundation we'll also use to, you know, set a frame for the budget and revisit the guidance. We aren't there yet, as Rodrigo already mentioned. Turning to PCB, you know, we have, for all provisions, a quarterly review. Every quarter we examine whether the provisioning level for known cases and the outlook on them, and whether some of these have materialized or matured enough that we can reliably estimate whether an exposure exists or not — then an adjustment would follow.
Werner Baumann
executiveYeah. Looking at it as of right now, we're basically discussing the close of quarter three, and there's nothing that would need to be provided for early on. On the personal injury case, yes, we have three more with a new suit, but it's very, very early on, so there's nothing we could say there. Then last but not least, also picking up on my earlier answer regarding recourse. In the accounting world, you know, we have to provide for exposures that are more likely than not to occur. Yeah. Which means they carry a likelihood of occurrence above 50% for an exposure. We are going to put a provision on the book with a few more criteria to be met. When it comes to recourse. We haven't booked anything because on the side of, let's say, accounts receivable for any claim that we have, the level of it, the standard is much higher, which means it has to be virtually certain that what we put on the books. Even though we are very confident that something good is going to come out of it for us, we cannot book anything at this point in time, which means from a timing perspective, it would always be disparate between what it is that we book early on, which is the exposure, and then recovery would come later.
Sachin Jain
analystAlright, thanks a lot, Werner.
Werner Baumann
executiveSure, happy to do it.
Oliver Maier
executiveThanks. Heidi, I know we're watching the clock here. I believe we have room for just 2 more questions at most.
Operator
operatorAbsolutely, we’ll take the following question now. Our next question is from Dominic Lunn at Credit Suisse. You’re live — please proceed.
Dominic Lunn
analystThanks a lot. Coming back to inflation once more — I believe you mentioned roughly EUR 1.3 billion of impact for the year so far, but how much of that landed specifically in Q3? My assumption is that this ought to roughly correspond to the minimum guidance for the coming few quarters. Second, on Nubeqa, when we look at the U.S. NBRx figures, which have really accelerated over recent weeks, presumably that eventually shows up in sales. I'd just like to hear your thinking on what's behind this apparent step change in utilization. Because I know previously you described ARASENS as perhaps more of a marketing tool that helps you cover the full range of prostate indications, but has this in fact gone beyond your own internal expectations, or is there something else you'd highlight?
Wolfgang Nickl
executiveSure, Dominic — I'll handle the inflation question first. We aren't giving quarter-by-quarter specifics, but you should figure Q3 came in above Q2, and Q2 came in above Q1. Looking ahead, instead of less, we're expecting somewhat more, given those inventory effects we mentioned, since a portion of it remains in inventory. You noticed the quarter-over-quarter increases there. It's going to rise from this point before, hopefully, declining later on.
Stefan Oelrich
executiveSo regarding Nubeqa, I believe you've got it right. What the label expansion does is let us speak more widely about how Nubeqa can be used. And that turns into greater usage. Keep in mind, we brought this product to market quite successfully during the heart of a pandemic, when our field resources were extremely limited. Those resources are now essentially fully restored. I think what's showing up at this point is that this is translating into prescription uptake too. So we're extremely happy. I can't claim we didn't anticipate it, since we were aware we had a best-in-class product in this case, and I think the evidence demonstrates that, and it's now reflected in prescriptions as well. So that's where we are. We're very, very pleased with how Nubeqa has performed.
Dominic Lunn
analystThat's great. Thanks so much.
Oliver Maier
executiveThanks, Dominic.
Operator
operatorThanks. We’ll take the last question now. It’s from Falko Friedrichs at Deutsche Bank. Go ahead — your line is open.
Falko Friedrichs
analystThanks a lot, and good afternoon. I have two questions, please. First, regarding your Consumer Health business, and particularly the Nutritionals part, do you see any risk of a possible slowdown in the coming quarters given all this inflation pressure on income levels, or do you expect it to hold up relatively well? Second, about the roughly EUR 500 million increase in your free cash flow guidance from lower net settlement payments, could you give a bit more detail on why those settlement payments came in below what you initially expected this year? Thank you.
Werner Baumann
executiveHi, Falko. Heiko will handle the first question, and after that Wolfgang is going to give us some insight into free cash flow.
Heiko Schipper
executiveSure. We've already observed Nutritionals decelerating somewhat in growth compared with, naturally, a really strong increase during the prior year and the one before that as well. What I'd say is that we've now settled into a new normal in that business. It has simply plateaued at a very elevated level. I don't anticipate it dropping sharply at this point. We shouldn't be assuming that. Some of the habits people developed across the last two years, in the post-COVID environment, where they began paying closer attention to their own personal health, are still very much in place. I believe people remain concerned about their immune system going forward, since immunity has been the primary factor driving that. Supplementation continues to be a very attractive space to operate in. Looking across the board at the impact of fairly substantial pricing actions being implemented throughout the industry, we aren't seeing any abrupt surge in private label growth, because we monitor that quite carefully. We obviously track it each quarter, checking in with consumers. They're clear in telling us that health stays their top priority, and that their way of coping with the price increases is, in one form or another, to seek out better deals, naturally, in the market.
Heiko Schipper
executiveWe're noticing certain shoppers shifting toward somewhat smaller sizes or value-oriented packs. So there may be a modest effect when it comes to volume. Honestly, that doesn't worry me much. I believe we're well positioned in that category, since the fundamental consumer behaviors around supplementation remain quite strong. I trust that addresses what you asked.
Wolfgang Nickl
executiveYeah. Falko, a quick question on free cash flow. Yes, you've got that right. The free cash flow improvements really do stem from lower settlement payouts. We began the year assuming roughly EUR 2.5 billion. At this point we've got it penciled in at EUR 2 billion. Year to date, across three quarters, we were at something like EUR 1.1 billion-EUR 1.2 billion. We'll see how that plays out. It could mean slightly more free cash. It could also be that we end up paying a bit less than that. The improvement clearly stems from the glyphosate complex. Obviously, I think you can appreciate this, with five wins under our belt, we're in no particular hurry either on the current program or on getting the futures program started. We review that as we go and keep our focus on winning more cases.
Falko Friedrichs
analystAlright, thanks.
Oliver Maier
executiveAppreciate that, Falko. I believe that question was the final one. I’d been waiting on Heidi—my apologies. Many thanks to everyone for spending your time and focus with us today. As always, it’s very much appreciated. With that, we conclude this call for the third quarter. Thanks, all. We’ll speak again soon.
Operator
operatorThat brings us to the end of today's conference call. We appreciate everyone for joining in. You're free to disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.